European Commission logo
English English
CORDIS - EU research results
CORDIS

A Non-Surgical Treatment to Restore Heart Valve Function

Project description

A simple, non-invasive treatment for a dangerous heart disease is on the way

The heart is a complex 4-chamber hydraulic system comprising pumps and valves. Normally, the tricuspid valve between the right atrium and ventricle opens to allow deoxygenated blood from the atrium into the ventricle. When the right ventricle contracts to pump the blood to the lungs for reoxygenation, the valve closes tightly to prevent blood from flowing backward. When the valve is damaged, the results can be lethal. Although severe tricuspid valve dysfunction is a highly prevalent condition, it has been relatively neglected. No longer the case, CVTVT has developed a device that can be delivered to the site non-invasively, restoring tricuspid valve function. Clinical trials and commercialisation will bring this simple life-saving device to patients.

Objective

"CroíValve is an innovative SME with the mission to lead the treatment of tricuspid valve disease and transform the lives of patients who currently face certain death.

In the US and EU, 550,000 patients present with tricuspid valve disease annually. Current treatment involves highly invasive, risky open-heart surgery and <1% receive this due to the risks involved. Recent clinical data is highlighting that the ""forgotten tricuspid valve"" must be treated.

CroíValve has developed a non-invasive device uniquely tailored to the challenges of the tricuspid valve. It is a small device that is delivered through a vein into the right heart, restoring the function of the tricuspid valve. Invented by a leading cardiologist, and refined by expert biomedical engineers, CroíValve’s is a non-surgical, safe, effective, easy to use solution for treating all patients with TR. It will transform patients’ lives, provide physicians a safe and straightforward treatment option and reduce the hospitalisations.

There is a significant market potential of > €2.5Bn/year. With H2020 SMEi funding, this Phase 2 Innovation Proposal will support the activities necessary to complete clinical trials and demonstrate safety and efficacy for CE Mark approval. Securing this grant, alongside private funding, will enable the company to expand its manufacturing capabilities, build up its sales and marketing infrastructure. CroíValve’s management team have a successful track record in the development, patenting and commercialisation of medical devices who can position the company as a leader in the treatment of tricuspid valve disease."

Keywords

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-2

Coordinator

CROIVALVE LIMITED
Net EU contribution
€ 2 494 970,00
Address
UNIT A GF, THE LIFFEY TRUST CENTRE, 117-125 UPPER SHERIFF STREET
D01 Y0E7 Dublin
Ireland

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Ireland Eastern and Midland Dublin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 5 450 186,50